Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 1731 to 1740 of 2586 total matches.

Anastrozole for Metastatic Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Jul 05, 1996  (Issue 978)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Anastrozole (Arimidex - Zeneca), a selective nonsteroidal aromatase inhibitor, has been approved by the US Food and Drug Administration (FDA) for treatment of postmenopausal women with advanced breast cancer that has progressed during treatment with tamoxifen (Nolvadex, and others).
Med Lett Drugs Ther. 1996 Jul 5;38(978):61-2 |  Show IntroductionHide Introduction

Samarium-153 Lexidronam for Painful Bone Metastases

   
The Medical Letter on Drugs and Therapeutics • Aug 29, 1997  (Issue 1008)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Samarium-153 lexidronam (Quadramet - Dupont Pharma) has been approved by the FDA for relief of pain in patients with osteoblastic bone metastases. Strontium-89 (Metastron) has been available for several years for this indication (Medical Letter, 35:102, 1993).
Med Lett Drugs Ther. 1997 Aug 29;39(1008):83-4 |  Show IntroductionHide Introduction

Imiquimod for Genital Warts

   
The Medical Letter on Drugs and Therapeutics • Dec 19, 1997  (Issue 1016)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Imiquimod (i mi kwi' mod) 5% cream (Aldara - 3M Pharmaceuticals) has been approved by the FDA for treatment of external genital and perianal warts (condyloma acuminata). The drug requires a prescription but is applied by the patient. It is the second patient-applied treatment to become available for external genital warts; the first was podofilox (Condylox - Medical Letter, 33:117, 1991).
Med Lett Drugs Ther. 1997 Dec 19;39(1016):118-9 |  Show IntroductionHide Introduction

A New Rabies Vaccine

   
The Medical Letter on Drugs and Therapeutics • Jun 19, 1998  (Issue 1029)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
RabAvert (Chiron), a new human rabies vaccine prepared in purified chick embryo cell culture (PCEC), has been marketed in the USA for pre- and post-exposure prophylaxis. It is available in other countries as Rabipur. Human rabies is rare in the United States, but thousands of people receive post-exposure prophylaxis every year (DL Noah et al, Ann Intern Med, 128:922, June 1, 1998).
Med Lett Drugs Ther. 1998 Jun 19;40(1029):64-5 |  Show IntroductionHide Introduction

Homeopathic Products

   
The Medical Letter on Drugs and Therapeutics • Feb 26, 1999  (Issue 1047)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Some patients may ask physicians about the effectiveness and safety of homeopathic drugs, which are marketed through health food stores, pharmacies, direct mail and person-to-person sales, and promoted for use in a wide range of disorders.
Med Lett Drugs Ther. 1999 Feb 26;41(1047):20-1 |  Show IntroductionHide Introduction

Prozac Weekly

   
The Medical Letter on Drugs and Therapeutics • Apr 02, 2001  (Issue 1101)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
The FDA has approved a new formulation of fluoxetine for once-weekly maintenance treatment of depression in patients who have responded to daily fluoxetine (Prozac).
Med Lett Drugs Ther. 2001 Apr 2;43(1101):27 |  Show IntroductionHide Introduction

Is Accutane really dangerous?

   
The Medical Letter on Drugs and Therapeutics • Sep 16, 2002  (Issue 1139)
The Medical Letter  On Drugs and Therapeutics www.medicalletter.org Published by The Medical ...
Isotretinoin (Accutane - Roche), an effective oral drug for treatment of acne, will soon be available generically. Concerns about its adverse effects, particularly psychiatric symptoms in adolescents, have been widely reported in the media.
Med Lett Drugs Ther. 2002 Sep 16;44(1139):82 |  Show IntroductionHide Introduction

In Brief: Vitamin B12 Nasal Spray

   
The Medical Letter on Drugs and Therapeutics • Aug 01, 2005  (Issue 1214)
Letter ® On Drugs and Therapeutics Volume 47 (Issue 1214) August 1, 2005 www.medicalletter.org ...
A nasal spray formulation of cyanocobalamin (Nascobal – Questcor) has been approved by the FDA for maintenance treatment of vitamin B12 deficiency. Nascobal is already available as an intranasal gel. Vitamin B12 deficiency, diagnosed by elevated serum concentrations of methylmalonic acid with or without elevated serum homocysteine and low serum B12 concentrations (<200 pg/mL), is common in older patients.1Since intestinal absorption of B12 may be impaired, the usual maintenance treatment of deficiency is intramuscular injection of the vitamin in doses of 1 mg every 4 weeks (after more...
Med Lett Drugs Ther. 2005 Aug 1;47(1214):64 |  Show IntroductionHide Introduction

In Brief: Measles Outbreak

   
The Medical Letter on Drugs and Therapeutics • Jun 02, 2008  (Issue 1287)
Letter ® On Drugs and Therapeutics Volume 50 (Issue 1287) June 2, 2008 www.medicalletter.org ...
The US Centers for Disease Control and Prevention (CDC) has reported that measles outbreaks have occurred in New York City, California and Arizona in 2008, and additional cases have been confirmed in Michigan, Wisconsin, Hawaii, New York State, Pennsylvania, Illinois and Virginia (CDC Health Advisory, May 1, 2008). To date, 63 of the 64 infected patients were unvaccinated, and 54 of the cases were associated with importation of the disease. Both measles infection and vaccination (2 doses at least 28 days apart, with the first dose no earlier than 12 months of age) generally provide lifelong...
Med Lett Drugs Ther. 2008 Jun 2;50(1287):41 |  Show IntroductionHide Introduction

Denosumab (Prolia) for Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Oct 18, 2010  (Issue 1349)
The Medical Letter® On Drugs and Therapeutics Volume 52 (Issue 1349) October 18, 2010 ...
The FDA has approved use of denosumab (Prolia – Amgen) for treatment of osteoporosis in postmenopausal women at high risk for fracture.
Med Lett Drugs Ther. 2010 Oct 18;52(1349):81-2 |  Show IntroductionHide Introduction